Helus Pharma Inc., a clinical-stage pharmaceutical company developing novel serotonergic agonists, has completed its legal name change from Cybin Inc., effective Oct. 1, 2026. The change, approved by shareholders at the company's annual and special meeting on Sept. 22, follows the adoption of the Helus Pharma business name in January and underscores the company's anticipated evolution from a clinical-stage discovery and development organization into a commercial-ready pharmaceutical company. The company's common shares will continue trading under the ticker HELP on the Nasdaq Global Market and Cboe Canada, and existing shareholders are not required to take any action.
The name change is more than a rebranding exercise; it signals Helus Pharma's strategic intent to position itself for the commercial phase of its lifecycle. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. It is also advancing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. These programs target large unmet needs in mental health, where existing therapies often fail to provide durable relief. By aligning its corporate identity with its late-stage pipeline, Helus Pharma aims to sharpen its focus on execution and potential commercialization.
The implications for investors and the broader biotech sector are significant. A name change that coincides with a transition toward commercialization can enhance visibility and credibility among institutional investors, partners, and patients. It also differentiates the company from its earlier incarnation as Cybin Inc., which was primarily known for early-stage discovery. As Helus Pharma, the company is signaling that its science has matured and that it is preparing for the regulatory and market challenges that accompany a commercial launch. This could attract new investment and strategic partnerships, particularly as the company advances HLP003 through Phase 3 trials.
Helus Pharma's approach focuses on proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. With class-leading data, the company aims to improve the treatment landscape for depression, anxiety, and other mental health conditions. Its operations span Canada, the United States, the United Kingdom, and Ireland, giving it a multinational footprint that could facilitate global commercialization. The company's pipeline also includes an extensive research portfolio of investigational NSAs, suggesting a sustained commitment to innovation beyond its current lead programs. For more details on the name change and corporate updates, the full press release is available at https://ibn.fm/rrJFh.
MissionIR, a communications platform that assists IR firms with syndicated content, disseminated the announcement. MissionIR operates within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. For more information about MissionIR, visit MissionIR. The company's full terms of use and disclaimers are available at https://www.MissionIR.com/Disclaimer.
